Literature DB >> 15869900

SOST/sclerostin, an osteocyte-derived negative regulator of bone formation.

Rutger L van Bezooijen1, Peter ten Dijke, Socrates E Papapoulos, Clemens W G M Löwik.   

Abstract

Sclerosteosis and Van Buchem disease are two closely related bone disorders characterized by progressive bone thickening due to increased bone formation. Sclerosteosis is associated with mutations in the SOST gene and Van Buchem disease with a 52 kb deletion downstream of the SOST gene that probably affects transcription of the gene. Expression of the gene product sclerostin in bone is restricted to osteocytes and it is a negative regulator of bone formation. It inhibits BMP-stimulated bone formation, but cannot antagonize all BMP responses. The exclusive bone phenotype of good quality of patients with sclerosteosis and Van Buchem disease and the specific localization of sclerostin make it an attractive target for the development of bone forming therapeutics.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15869900     DOI: 10.1016/j.cytogfr.2005.02.005

Source DB:  PubMed          Journal:  Cytokine Growth Factor Rev        ISSN: 1359-6101            Impact factor:   7.638


  109 in total

1.  Circulating sclerostin in disorders of parathyroid gland function.

Authors:  Aline G Costa; Serge Cremers; Mishaela R Rubin; Donald J McMahon; James Sliney; Marise Lazaretti-Castro; Shonni J Silverberg; John P Bilezikian
Journal:  J Clin Endocrinol Metab       Date:  2011-09-21       Impact factor: 5.958

Review 2.  Inflammatory bone loss: pathogenesis and therapeutic intervention.

Authors:  Kurt Redlich; Josef S Smolen
Journal:  Nat Rev Drug Discov       Date:  2012-03-01       Impact factor: 84.694

Review 3.  Recent biological trends in management of fracture non-union.

Authors:  Khaled M Emara; Ramy Ahmed Diab; Ahmed Khaled Emara
Journal:  World J Orthop       Date:  2015-09-18

Review 4.  Glucocorticoid-Induced Osteoporosis.

Authors:  Baruch Frenkel; Wendy White; Jan Tuckermann
Journal:  Adv Exp Med Biol       Date:  2015       Impact factor: 2.622

Review 5.  Diseases of Wnt signaling.

Authors:  Mark L Johnson; Nalini Rajamannan
Journal:  Rev Endocr Metab Disord       Date:  2006-06       Impact factor: 6.514

Review 6.  Emerging therapeutic opportunities for skeletal restoration.

Authors:  Masanobu Kawai; Ulrike I Mödder; Sundeep Khosla; Clifford J Rosen
Journal:  Nat Rev Drug Discov       Date:  2011-02       Impact factor: 84.694

Review 7.  Regulatory pathways revealing new approaches to the development of anabolic drugs for osteoporosis.

Authors:  T J Martin; N A Sims; K W Ng
Journal:  Osteoporos Int       Date:  2008-03-13       Impact factor: 4.507

Review 8.  Osteocytes, mechanosensing and Wnt signaling.

Authors:  Lynda F Bonewald; Mark L Johnson
Journal:  Bone       Date:  2008-01-12       Impact factor: 4.398

Review 9.  Osteoblast dysfunctions in bone diseases: from cellular and molecular mechanisms to therapeutic strategies.

Authors:  Pierre J Marie
Journal:  Cell Mol Life Sci       Date:  2014-12-09       Impact factor: 9.261

10.  Serum sclerostin levels decline in post-menopausal women with osteoporosis following treatment with intermittent parathyroid hormone.

Authors:  S Piemonte; E Romagnoli; C Bratengeier; W Woloszczuk; A Tancredi; J Pepe; C Cipriani; S Minisola
Journal:  J Endocrinol Invest       Date:  2012-07-24       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.